News

Over a 48-week stretch, a composite end point analysis suggested a survival treatment benefit with edaravone, further supporting its use in patients with ALS.

Alex Whiting, MD, director of epilepsy surgery at Allegheny Health Network, discussed the challenges with drug-resistant epilepsy, and how clinicians can initiate conversations about potential options for their patients.

Here's some of what is coming soon to NeurologyLive® this week.

In 2 pivotal phase 3 trials, atogepant met its primary end point of superior reduction in monthly migraine days vs placebo, with consistent safety throughout.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

A duo of experts from the pivotal, phase 3 ASPEN trial shared commentary on the impact of daxibotulinumtoxinA’s approval for adults with cervical dystonia.

IMU-838, or vidofludimus calcium, has shown promising results in studies of patients with relapsing-remitting multiple sclerosis.

Neurology News Network for the week ending August 19, 2023. [WATCH TIME: 4 minutes]

The approval was based on the phase 3 KINECT-HD study, an 128-patient cohort trial in which valbenazine met its primary end point, demonstrating a statistically significant reduction in UHDRS TMC scores vs placebo.

Women who reported a history of hypertensive disorders of pregnancy were estimated to have 1.66 times the risk of stroke relative to parous women who had not had those pregnancy complications.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 18, 2023.

A peer-reviewed analysis revealed critical gaps in care for patients with Parkinson disease in the United States, including disparities affecting women, people of color, and residents of rural areas.

The headache specialist at the Hartford Healthcare Headache Center discussed findings from a study that revealed altered retinal vasculature in individuals with migraine with aura, indicating potential retinal biomarkers for disease progression. [WATCH TIME: 4 minutes]

Elevated caregiver depression risk corresponds to increased emergency department usage, hinting at a pivotal link between caregiver well-being and patient healthcare utilization.

Adam Naj, PhD, genetic epidemiologist at the University of Pennsylvania, discussed the importance of collecting genetic data from diverse ancestries to investigate the risk of Alzheimer Disease.

Patients on IPX203 received less doses than those on traditional immediate-release carbidopa/levodopa and demonstrated 0.53 more hours of good ON time per day than IR CD/LD.

The executive vice president of the National MS Society discussed the challenges with treating progressive forms of MS, and the accumulating neurodegeneration seen over time. [WATCH TIME: 4 minutes]

Over the 36-month treatment period, nonambulatory patients with SMA treated with apitegromab showed improvements in patient-reported outcomes of daily living and fatigue.

The senior vice president of research at Vaxxinity discussed recently published trial findings on a novel vaccine that targets Alzheimer disease and triggers the production of antibodies against toxic amyloid-ß peptides. [WATCH TIME: 9 minutes]

The phase 2 trial represented the first-ever clinical data to be published of an oral orexin agonist for patients living with narcolepsy type 1.

AOC 1044, an exon 44-targeting agent, holds potential to fill a major unmet need for patients with Duchenne muscular dystrophy, as there are currently there are no approved therapies approved targeting this mutation.

Although the association between genetically predicted insomnia and risk of sepsis was mediated through cardiometabolic risk factors, the data still point to a clear link between the two conditions.

A new platform showed the ability to effectively detect patients with synucleinopathies using serum samples, improving the time and accuracy for diagnosis of specific neurodegenerative diseases such as Parkinson disease.

The associate professor at Yeshiva University and Albert Einstein College of Medicine discussed the significance of motivational interviewing as a means for providers to engage with their patients and the harmful impact of societal stereotypes on individuals with migraine. [WATCH TIME: 5 minutes]

The neurosurgeon at Allegheny Health Network provided perspective on how GammaTile therapy is revolutionizing neurosurgery and post-operative processes of brain tumors.

Foralumab, a therapy designed to bind to T cell receptor, is about to be assessed in phase 2 trials of patients with non-active secondary progressive multiple sclerosis in the third quarter of 2023.

At 6 weeks post-treatment, the patient saw clinical improvements in multiple domains, including autonomic function, vocalization, gross motor skills, and fine motor skills and hand function.

The associate vice president of neuroscience, US Medical Affairs at Eli Lilly discussed the complexities of migraine treatment, highlighting the need to address communication barriers between healthcare providers and patients. [WATCH TIME: 5 minutes]

In a phase 3 study and open-label extension, patients treated with daxibotulinumtoxinA showed significant improvements in their condition, explained by changes on the Toronto Western Spasmodic Torticollis Rating Scale.

The associate professor of pediatrics in neurology and epilepsy at Northwestern University Feinberg School of Medicine discussed the FDA-cleared phase 1/2 trial of an exon 50 skipping therapy to address the specific mutations causing Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]